Strategies adopted by gastric pathogen Helicobacter pylori for a mature biofilm formation: Antimicrobial peptides as a visionary treatment

Microbiol Res. 2023 Aug:273:127417. doi: 10.1016/j.micres.2023.127417. Epub 2023 May 26.

Abstract

Enormous efforts in recent past two decades to eradicate the pathogen that has been prevalent in half of the world's population have been problematic. The biofilm formed by Helicobacter pylori provides resistance towards innate immune cells, various combinatorial antibiotics, and human antimicrobial peptides, despite the fact that these all are potent enough to eradicate it in vitro. Biofilm provides the opportunity to secrete various virulence factors that strengthen the interaction between host and pathogen helping in evading the innate immune system and ultimately leading to persistence. To our knowledge, this review is the first of its kind to explain briefly the journey of H. pylori starting with the chemotaxis, the mechanism for selecting the site for colonization, the stress faced by the pathogen, and various adaptations to evade these stress conditions by forming biofilm and the morphological changes acquired by the pathogen in mature biofilm. Furthermore, we have explained the human GI tract antimicrobial peptides and the reason behind the failure of these AMPs, and how encapsulation of Pexiganan-A(MSI-78A) in a chitosan microsphere increases the efficiency of eradication.

Keywords: Antibiotics; Antimicrobial peptides (LL-37, HBD3, MSI-78 against H. pylori); Biofilm; Chemotaxis (Tlps, Che proteins, Flagellar motor switch rotation); Helicobacter pylori.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Antimicrobial Peptides
  • Biofilms
  • Helicobacter Infections* / drug therapy
  • Helicobacter pylori*
  • Humans

Substances

  • Antimicrobial Peptides
  • Anti-Bacterial Agents